Ironwood Pharmaceuticals, Inc.
IRWD
$0.5944
-$0.0546-8.41%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | 41.14M | 90.55M | 91.59M | 94.40M | 74.88M |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 41.14M | 90.55M | 91.59M | 94.40M | 74.88M |
Cost of Revenue | 27.43M | -78.48M | 29.83M | 30.39M | 25.82M |
Gross Profit | 13.71M | 169.02M | 61.77M | 64.01M | 49.06M |
SG&A Expenses | 24.26M | 33.59M | 36.11M | 36.56M | 37.61M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 51.69M | 58.98M | 65.94M | 66.95M | 63.42M |
Operating Income | -10.55M | 31.56M | 25.65M | 27.44M | 11.46M |
Income Before Tax | -36.27M | 24.00M | 17.37M | 18.88M | 4.96M |
Income Tax Expenses | 1.11M | 21.74M | 13.72M | 19.74M | 9.12M |
Earnings from Continuing Operations | -37.39M | 2.26M | 3.65M | -860.00K | -4.16M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -37.39M | 2.26M | 3.65M | -860.00K | -4.16M |
EBIT | -10.55M | 31.56M | 25.65M | 27.44M | 11.46M |
EBITDA | -10.07M | 32.05M | 26.56M | 27.55M | 11.97M |
EPS Basic | -0.23 | 0.01 | 0.02 | -0.01 | -0.03 |
Normalized Basic EPS | -0.07 | 0.09 | 0.07 | 0.08 | 0.02 |
EPS Diluted | -0.23 | 0.01 | 0.02 | -0.01 | -0.03 |
Normalized Diluted EPS | -0.07 | 0.09 | 0.07 | 0.08 | 0.02 |
Average Basic Shares Outstanding | 160.97M | 159.45M | 159.71M | 159.01M | 157.70M |
Average Diluted Shares Outstanding | 160.97M | 159.45M | 160.23M | 159.01M | 157.70M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |